drugset / Trial / NCT01290354

Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer

NCT01290354

Phase 1 Completed 10 enrolled GlaxoSmithKline
NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to find out how much lapatinib can enter both normal brains and brains in which tumours secondary to breast cancer have developed.

Timeline

Start
2011-09-12
Primary completion
2013-03-18
Completion
2013-03-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Lapatinib Small molecule 20 ug Intravenous
Subject Lapatinib Small molecule 1500 mg Oral

Indications